test: Indications, Dosage, Precautions, Adverse Effects
Россия
  • Россия
  • Украина

test

Table 1 ACR Responses in MTX/Placebo-Controlled Trials (Percent of Patients)
Study I MTX-Naïve Study II Inadequate Response to MTX Study III Inadequate Response to MTX Study IV Inadequate Response to DMARD Study V Inadequate Response to anti-TNF Agent
Response Rate ACT 8 mg/kg n=286 MTX n=284 ACT 8 mg/kg +MTX n=398 Placebo + MTX n=393 ACT 8 mg/kg +MTX n=205 Placebo + MTX n=204 ACT 8 mg/kg + DMARD n=803 Placebo + DMARD n=413 ACT 8 mg/kg +MTX n=170 Placebo + MTX n=158
ACR 20
Week 24 70%*** 52% 56%*** 27% 59%*** 26% 61%*** 24% 50%*** 10%
Week 52^ 56%*** 25%
ACR 50
Week 24 44%** 33% 32%*** 10% 44%*** 11% 38%*** 9% 29%*** 4%
Week 52^ 36%*** 10%
ACR 70
Week 24 28%** 15% 13%*** 2% 22%*** 2% 21%*** 3% 12%** 1%
Week 52^ 20%*** 4%
MCR† by Week 52^ 7% 1%